top of page
Regulatory and Ethics Requirements

The main objectives of Work Package Four are to:

Identify relevant clinical trial regulatory and ethics requirements

Identify, map and translate national regulations and ethics processes (and associated requirements) into standardised operational guidelines and templates, available through the CTC platform.

Capture metrics associated with ethics and regulatory review

Operationalise country regulations and ethics process and requirements.

Promote digital clinical trial application, review, and approval

Promote a centralised online functionality for submission and approvals of clinical trials applications to national regulatory authorities but also as part of the ethics application to  Institutional Review Boards (IRB).

Description of Work

What and Why

  • To translate country regulations and ethics processes and requirements into ready-to-use operational guidelines and templates and upload them onto the CTC platform.

 

Goals

  • Identify, map and translate national regulations and ethics processes (and associated requirements) into standardised operational guidelines and templates, available through the CTC platform.

  • Capture metrics associated with ethics and regulatory review.

  • Promote a centralised online functionality for submission and approvals of clinical trials applications to national regulatory authorities but also as part of the ethics application to IRBs.

 

Activities

  • Task 4.1: Identify relevant clinical trial regulatory and ethics requirements.

  • Task 4.2: Operationalise country regulations and ethics process and requirements.

  • Task 4.3: Promote digital clinical trial application, review, and approval through CTC platform.

 

Expected outcomes

  • Regulatory and Ethics Operational Templates and Process Maps.

  • Predictable timelines for clinical trial applications, and harmonised and predictable clinical trial regulations will bring more clinical trials to the country.

 

Freedoms

  • Existing relationship with relevant stakeholders.

  • The formation of AMA and opportunities for synergy.

 

Constraints

  • Limited resources.

  • Lack of harmonisation across national regulatory agencies.

Responsible Consortium Partners

890.png
bottom of page